EC Number   |
Inhibitors |
Structure  |
|---|
   3.4.24.82 | more |
no inhibitory effect of alpha1-antitrypsin |
 |
| 3.4.24.82 | more |
ADAMTS-4 is not inhibited by 125 nM or less tissue inhibitor of metalloproteinase-1 |
|
| 3.4.24.82 | more |
no inhibition by tissue inhibitor of metalloproteinases 1 or tissue inhibitor of metalloproteinases 2 at 100 nM |
|
| 3.4.24.82 | more |
no inhibition of ADAMTS4 deletion mutants including DELTASp (DELTAArg693-Lys837, lacking the spacer domain) |
|
| 3.4.24.82 | more |
substrate specificity of ADAMTS-4 against recombinant aggrecan, aggrecan mutants V356A-V361A-E362D, V361Q-E362K, D360H-V361Q-E362K, S377Q lead to aggrecan cleavage inhibition |
|
| 3.4.24.82 | more |
lower expression level in majority of primary tumors |
|
| 3.4.24.82 | more |
down-regulation of IL-1beta-induced ADAMTS-4 activation by Ras knockdown or inhibition of reactive oxygen species by antioxidants along with ablation of MyD88, IRAK1, or TRAF6; inducing effect of IL-1beta partially blocked by knockdown of adaptor proteins MyD88, IRAK1 or TRAF6 |
|
| 3.4.24.82 | more |
design of ADAMTS-4 inhibitors. No inhibition observed with the ADAMTS-5 inhibitors: 2-[4-(benzyloxy)phenyl]-3-oxoisoindoline-4-carboxylic acid or 2-[4-(benzyloxy)phenyl]-N-hydroxy-3-oxoisoindoline-4-carboxamide |
|
| 3.4.24.82 | more |
design and development for potent and selective inhibitors of ADAMTS-4 and ADAMTS-5 |
|
| 3.4.24.82 | EDTA |
5 mM, complete inhibition |
  |
